Notice2023-02725
Certain Selective Thyroid Hormone Receptor-Beta Agonists, Processes for Manufacturing or Relating to Same, and Products Containing Same; Institution of Investigation
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 9, 2023
Issuing agencies
International Trade Commission
Abstract
Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on December 29, 2022, under section 337 of the Tariff Act of 1930, as amended, on behalf of Viking Therapeutics, Inc. of San Diego, California. A supplement was filed on January 13, 2023. The complaint, as supplemented, alleges violations of section 337 based upon the importation into the United States of certain selective thyroid hormone receptor-beta agonists, processes for manufacturing or relating to same, and products containing same by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure a domestic industry or prevent the establishment of a domestic industry. The complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 27 (Thursday, February 9, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 27 (Thursday, February 9, 2023)]
[Notices]
[Pages 8455-8457]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-02725]
=======================================================================
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Inv. No. 337-TA-1352]
Certain Selective Thyroid Hormone Receptor-Beta Agonists,
Processes for Manufacturing or Relating to Same, and Products
Containing Same; Institution of Investigation
AGENCY: International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on December 29, 2022, under section
337 of the Tariff Act of 1930, as amended, on behalf of Viking
Therapeutics, Inc. of San Diego, California. A supplement was filed on
January 13, 2023. The complaint, as supplemented, alleges violations of
section 337 based upon the importation into the United States of
certain selective thyroid hormone
[[Page 8456]]
receptor-beta agonists, processes for manufacturing or relating to
same, and products containing same by reason of misappropriation of
trade secrets, the threat or effect of which is to destroy or
substantially injure a domestic industry or prevent the establishment
of a domestic industry. The complainant requests that the Commission
institute an investigation and, after the investigation, issue a
limited exclusion order and cease and desist orders.
ADDRESSES: The complaint, except for any confidential information
contained therein, may be viewed on the Commission's electronic docket
(EDIS) at <a href="https://edis.usitc.gov">https://edis.usitc.gov</a>. For help accessing EDIS, please email
<a href="/cdn-cgi/l/email-protection#e1a4a5a8b2d2a9848d91a19492889582cf868e97"><span class="__cf_email__" data-cfemail="a5e0e1ecf696edc0c9d5e5d0d6ccd1c68bc2cad3">[email protected]</span></a>. Hearing impaired individuals are advised that
information on this matter can be obtained by contacting the
Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at <a href="https://www.usitc.gov">https://www.usitc.gov</a>.
FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S. International Trade Commission,
telephone (202) 205-2560.
SUPPLEMENTARY INFORMATION:
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on February 3, 2023, ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(A) of section 337 in the
importation into the United States of certain products identified in
paragraph (2) by reason of misappropriation of trade secrets, the
threat or effect of which is to destroy or substantially injure a
domestic industry in the United States or prevent the establishment of
an industry in the United States;
(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language
description of the accused products or category of accused products,
which defines the scope of the investigation, is ``drug products and
drug substances that are selective thyroid hormone receptor-beta
agonists for the treatment of metabolic disorders and liver diseases'';
(3) Pursuant to section 210.10(b)(3) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(3), the presiding
Administrative Law Judge shall hold an early evidentiary hearing, find
facts, and issue an early decision, within 100 days of institution
except for good cause shown, as to whether complainant can show that
the threat or effect of the alleged unfair acts is to (i) to destroy or
substantially injure an industry in the United States, or (ii) to
prevent the establishment of such an industry. Notwithstanding any
Commission Rules to the contrary, which are hereby waived, any such
decision should be issued in the form of an initial determination (ID)
under Commission Rule 210.42(a)(3), 19 CFR 210.42(a)(3). The ID will
become the Commission's final determination 30 days after the date of
service of the ID unless the Commission determines to review the ID.
Any such review will be conducted in accordance with Commission Rules
210.43, 210.44, and 210.45, 19 CFR 210.43, 210.44, and 210.45. The
issuance of an early ID finding that complainant failed to demonstrate
that the threat or effect of the alleged unfair acts is (i) to destroy
or substantially injure an industry in the United States, or (ii) to
prevent the establishment of such an industry shall stay the
investigation unless the Commission orders otherwise; any other
decision shall not stay the investigation or delay the issuance of a
final ID covering the other issues of the investigation. Commissioner
Schmidtlein does not support the use of a 100-day proceeding in this
investigation. See concurrently filed Memorandum No. C086-VV-002
(February 3, 2023);
(4) Pursuant to Commission Rule 210.50(b)(l), 19 CFR 210.50(b)(1),
the presiding administrative law judge shall take evidence or other
information and hear arguments from the parties or other interested
persons with respect to the public interest in this investigation, as
appropriate, and provide the Commission with findings of fact and a
recommended determination on this issue, which shall be limited to the
statutory public interest factors set forth in 19 U.S.C. 1337(d)(l),
(f)(1), (g)(1);
(5) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
(a) The complainant is:
Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San
Diego, CA 92121
(b) The respondents are the following entities alleged to be in
violation of section 337, and are the parties upon which the complaint
is to be served:
Ascletis Pharma Inc., 12/F, Building D, 198 Qidi Road, HIPARK, Xiaoshan
District, Hangzhou, Zhejiang Province, China 312000
Ascletis Pharmaceuticals Co. Ltd., No.1, Yunhai Road, Lihai Town,
Binhai New Town, Shaoxing, Zhejiang Province, China 312000
Ascletis Bioscience Co., Ltd., 12F, Building D, 198 Qidi Road, HIPARK,
Xiaoshan District, Hangzhou, Zhejiang Province, China 311200
Gannex Pharma Co., Ltd., 3F, No. 665 Zhangjiang Road, Pilot Free Trade
Zone, Shanghai, China 200000
Jinzi Jason Wu, 3413 E. Pine Street, Seattle, WA 98122
(c) The Office of Unfair Import Investigations, U.S. International
Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and
(6) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the notice of investigation must be
submitted by the named respondents in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798
(March 19, 2020), such responses will be considered by the Commission
if received not later than 20 days after the date of service by the
complainant of the complaint and the notice of investigation.
Extensions of time for submitting responses to the complaint and the
notice of investigation will not be granted unless good cause therefor
is shown.
Failure of a respondent to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
By order of the Commission.
Authority: The authority for institution of this investigation is
contained in section 337 of the Tariff Act of 1930, as amended, 19
U.S.C.
[[Page 8457]]
1337, and in section 210.10 of the Commission's Rules of Practice and
Procedure, 19 CFR 210.10 (2022).
Issued: February 3, 2023.
Katherine Hiner,
Acting Secretary to the Commission.
[FR Doc. 2023-02725 Filed 2-8-23; 8:45 am]
BILLING CODE 7020-02-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 9, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.